Advertisement

African Medicinal Mushrooms: Source of Biopharmaceuticals for the Treatment of Noncommunicable Diseases – A Review

  • Kenneth Anchang Yongabi
Chapter

Abstract

African mushrooms remain underexploited for biopharmaceuticals for application in modern medicine. Yet, amidst the rich use of mushrooms in African folk medicine and the high rates of endemic diseases plaguing the continent, the need for a critical exposé of African mushrooms as biopharmaceuticals and phytoceuticals is imperative and hereby presented. Generally, mushrooms are rich sources of many bioactive compounds that are important to our health servicing. They are a good source of proteins that are important to all body functions. Mushroom proteins are of very high quality and are rich in the most important essential amino acids. They are an excellent source of most B vitamins, and the primary natural source of ergosterol or provitamin D, and also essential minerals such as zinc and selenium. Malnutrition and stunting are largely a health problem in rural Africa. Mushrooms are abundant in nutrients that can potentially stamp out nutritional deficiencies in African children. While many people who eat balanced diets receive all the needed minerals, some get more sodium than they need. Mushrooms have the benefits of low sodium, low cholesterol, and higher potassium and iron than most foods. Chitin which is present in many African mushrooms such as Pleurotus tuber-regium, Termitomyces spp., Pleurotus spp., and Agaricus spp. is the primary structural material in mushrooms and has been shown to be of immense value as dietary fiber. It can also be hydrolyzed to glucosamine, which is widely accepted by physicians for treatment of chronic diseases of aging people such as autoimmune disorders and arthritis. Also it is used as a valuable food supplement for the prevention and alleviation of osteoarthritis. β-Glucans widely identified in a number of African mushrooms such as Ganoderma spp., African truffles, and Agaricus spp. are valuable immune regulatory substances that can treat and manage different cancers, diabetes, and other cardiovascular disorders.

Keywords

β-Glucans Chitosans Chitin Dietary fiber Glucosamine Medicinal mushroom Noncommunicable diseases Osteoarthritis Selenium 

Abbreviations

DNA

Deoxyribonucleic acid

FDA

Food and Drug Administration

HDL

High-density lipoprotein

LDL

Low-density lipoprotein

NCDs

Noncommunicable Diseases

References

  1. Albershiem P (1976) The primary cell wall. In: Bonner J, Varner JE (eds) Plant biochemistry, 3rd edn. Academic, New York, pp 226–274Google Scholar
  2. Aoyagi Y, Kasuga A, Sasaki H, Matuzawa M, Tsutagawa Y, Kawai H (1993) Chemical composition of shitake mushroom cultivated on logs and sawdust substrate beds and their relations to composition of the substrate. Nippon Shokuhin Kogyo Gakkaishi 40:771–775CrossRefGoogle Scholar
  3. Austin PR, Brine CJ, Castle JE, Zikakis JP (1981) Chitin: new facets of research. Science 212:749–753CrossRefGoogle Scholar
  4. Bano Z, Bhagya S, Srinivasan KS (1981) Essential amino acid composition and proximate analysis of the mushroom Pleurotus eous and P. florida. Mushroom Newslett Trop 1(3):6–10Google Scholar
  5. Braham R, Dawson B, Goodman C (2003) The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med 37:45–49CrossRefGoogle Scholar
  6. Brzezinski R, LeHoux JG, Kelly A (2004) Clinical studies on the innocuousness of chitosan and its short-chain derivative generated by enzymatic hydrolysis. Asia Pacific J Clin Nutr 13:S96Google Scholar
  7. Chang ST (1972) The Chinese mushroom. The Chinese University of Hong Kong, Hong Kong, p 113Google Scholar
  8. Chang ST (1993) Mushroom biology: the impact on mushroom production and mushroom products. In: Chang et al (eds) Mushroom biology and mushroom products. The Chinese University Press, Hong Kong, pp 3–20Google Scholar
  9. Chang ST (1999) Global impact of edible and medicinal mushrooms on human welfare in the 21st Century: non-green revolution. Int J Med Mushrooms 1:1–7.  https://doi.org/10.1615/IntJMedMushrooms.v1.i1.10 CrossRefGoogle Scholar
  10. Cheung PC (1998) Plasma and hepatic cholesterol levels and fecal neutral sterol excretion are altered in hamsters fed straw mushroom diets. J Nutr 128:1512–1516CrossRefGoogle Scholar
  11. Chioza A, Ohga S (2014) Cultivated mushrooms in Malawi: a look at the present situation. Adv Microbiol 4(1):6–1174CrossRefGoogle Scholar
  12. Cho YW, Cho YN, Chung SH, Yoo G, Ko SW (1999) Water-soluble chitin as a wound healing accelerator. Biomaterials 20:2139–2145CrossRefGoogle Scholar
  13. Fenton JI, Chlebek-Brown KA, Peters TL, Carson JP, Orth MW (2000) Glucosamine HCL reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 8:258–265CrossRefGoogle Scholar
  14. Foster AB, Webber JM (1960) Chitin. Adv Carbohydrate Chem 15:371–393Google Scholar
  15. Furda I (1983) Aminopolysaccharides-their potential as dietary fiber. In: Furda I (ed) Unconventional sources of dietary fibers. American Chemical Society, Washington, DC, pp 105–122CrossRefGoogle Scholar
  16. Gallaher DD, Gallaher CM, Mahrt GJ, Carr TP, Hollingshead CH, Heslink R Jr, Wise J (2002) A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am College Nutr 21:428–433CrossRefGoogle Scholar
  17. Gordon DT, Williford CB (1983) Chitin and chitosan: influence on absorption in rats. In: Furda I (ed) Unconventional sources of dietary fibers. American Chemical Society, Washingon, DC, pp 155–184CrossRefGoogle Scholar
  18. Katz DL (2001) A scientific review of the health benefit of oats. The Quaker Oats Company. http://www.quakeroatmeal.com/healthpros/IHP/HealthBenefitsofOats.pdf
  19. Kogure T (1975) On the specificity of mushroom Pleurotus ostreatus and Pleurotus spodoleucus extracts. Vox Sanguinis 29:221–227CrossRefGoogle Scholar
  20. Kurtzman RH Jr (1975) Mushrooms as a source of food proteins. In: Friedman M (ed) Protein nutritional quality of foods and feeds, part 2. Marcel Dekker, New York, pp 305–318Google Scholar
  21. Kurtzman RH Jr (1991) Dolomite upsets the carbon dioxide balance. Mushroom Sci 13:747–751Google Scholar
  22. Kurtzman RH Jr (1993) Analysis, digestibility and the nutritional value of mushrooms. In: Chang et al (eds) Mushroom biology and mushroom products. Chinese University Press, ShatinGoogle Scholar
  23. Kurtzman RH Jr (1997) Nutrition from mushrooms, understanding and reconciling available data. Mycoscience 40:247–253CrossRefGoogle Scholar
  24. Mattila P, Lampi AM, Ronkainen R, Toivo J, Piironen V (2002) Sterols and vitamin D2 contents in some wild and cultivated mushrooms. Food Chem 76:293–298.  https://doi.org/10.1016/S0308-8146(01)00275-8 CrossRefGoogle Scholar
  25. McCarty MF (1998) Enhanced synovial production of hyaluronic acid may explain rapid clinical responses to high-dose glucosamine in osteoarthritis. Med Hypotheses 50(6):507–510CrossRefGoogle Scholar
  26. Mello DM, Brian MS, Nielson D et al (2004) Comparison of inhibitory effects of glucosamine and mannosamine on bovine articular cartilage degradation in vitro. Am J Vet Res 65:1440–1445.  https://doi.org/10.2460/ajvr.2004.65.1440 CrossRefPubMedGoogle Scholar
  27. Mpeketula PMG (2008) Indigenous mushroom species cultivation, processing and utilization for food security and conservation. National Research Council of Malawi, Conference Proceedings, Malawi, pp 95–105Google Scholar
  28. Noller CR (1951) Chemistry of organic compounds. WB Saunders, Philadelphia, p 885Google Scholar
  29. Okhuoya JA, Akpaja EO, Osemwegie OO, Oghenekaro AO, Ihayaere CA (2010) Nigerian mushrooms: underutilized non-wood forest resources. Environ Manag 14(1):43–54Google Scholar
  30. Ormrod DJ, Holmes CC, Miller TE (1998) Dietary chitosan inhibits hypercholesterolemia and atherogenesis in apolipoprotein E-deficient mouse model of atherosclerosis. Atherosclerosis 138(2):329–334CrossRefGoogle Scholar
  31. Orth MW, Peters TL, Hawkins JN (2002) Inhibition of articular cartilage degradation by glucosamine-HCL and chondroitin sulfate. Equine Vet J Suppl 34:224–229CrossRefGoogle Scholar
  32. Ortiz R, Sanchez R, Piez A, Montaio LF, Zenteno E (1992) Induction of intestinal malabsorption syndrome in rats fed with Agaricus bisporus mushroom lectin. J Agric Food Chem 40:1375–1378CrossRefGoogle Scholar
  33. Outila T, Mattila PH, Piironen VI, Lamberg-Allardt CJ (1999) Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay. Am J Clin Nutr 69:95–98CrossRefGoogle Scholar
  34. Presant P, Kornfeld S (1972) Characterization of the cell surface receprot for the Agaricus bisporus Hemagglutinin. J Biol Chem 247(21):6937–6945PubMedGoogle Scholar
  35. Razdan A, Pettersson R (1994) Effect of chitin and chitosan on nutrient digestibility and plasma lipid concentrations in broiler chickens. Br J Nutr 72:277–288CrossRefGoogle Scholar
  36. Robson G (1999) Hyphal cell biology. In: Oliver RP, Schweizer M (eds) Molecular fungal biology. Cambridge University Press, Cambridge, pp p164–p184CrossRefGoogle Scholar
  37. Sanchez JE, Huerta G, Montiel E (eds) (2002) Mushroom biology and mushroom products, Proceedings of the 1V international conference. University of Morelos, Cuernavaca, Mexico, p 468Google Scholar
  38. Su CH, Lin BW, Yu SY, Liu SW (2004) Use of Ganoderma tsugae for the treatment of human chronic skin ulcers. Mushroom Sci 16:659–662Google Scholar
  39. Wakita S (1976) Thiamine-destruction by mushrooms. Sci Rep Yokohama Natl Univ Sect 2 23:39–70Google Scholar
  40. Windholtz M (1983) The Merck Index, 10th ed. Merck & Co., Rahway, pp 1463–1481Google Scholar
  41. Wittliff JL, Airth RL (1970) Thiaminase I. (Thiamine: base 2-methyl-4aminopyrimidine-5-methenyl transferase, EC 2.5.1.2). Methods Enzymol 18(A):234–238.  https://doi.org/10.1016/0076-6879(71)18310-3 CrossRefGoogle Scholar
  42. Yongabi KA (2007) Ethnomycology of grassland fields and tropical rainforest of Cameroon. Poster presentation at the ‘First World Conference on Conservation and Sustainable Use of Wild Fungi’, organized by the Regional Government of Andalucia, Spain, 10–16 December, pp 298–299Google Scholar
  43. Yongabi A (2014) Current developments in mushroom biotechnology in sub Saharan Africa. WSMBMP Bull 11:4–13Google Scholar
  44. Yongabi K, Agho M, Martinez-Carrera D (2004) Ethnomycological studies on wild mushrooms in Cameroon, Central Africa. Micologia Aplicada Int 16(2):34–36Google Scholar
  45. Yongabi A, Laura D, Keto M, Suki KKM, Alex D, Francisca NN (2015) Can we exploit and adapt indigenous knowledge and ethnobotanicals for a healthy living in the face of emerging diseases like Ebola in Africa. Am J Clin Exp Med 3:24–28.  https://doi.org/10.11648/jcem.s.2015030101.15 CrossRefGoogle Scholar
  46. Yusof NL, Wee A, Lim LY, Khor E (2003) Flexible chitin films as potential wound-dressing materials: wound model studies. J Biomed Mater: Res A 66(2):224–232CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Kenneth Anchang Yongabi
    • 1
    • 2
    • 3
  1. 1.Phytobiotechnology Research FoundationBamendaCameroon
  2. 2.Ebonyi State UniversityAbakalikiNigeria
  3. 3.Imo State UniversityOwerriNigeria

Personalised recommendations